Home Blog Page 1926

IBM Announces New Platform for Financial Institutions and Regulated Enterprises Entering the Digital Asset Economy

By
Advertorial Desk
-

With IBM Digital Asset Haven, clients can manage digital assets across various blockchains, all while conforming to their sovereignty, security, and compliance requirements

ARMONK, N.Y., Oct. 27, 2025 /PRNewswire/ — IBM (NYSE: IBM) today announced the launch of IBM Digital Asset Haven, a comprehensive platform for financial institutions, governments, and corporations to securely manage and scale their digital asset operations. Banks and governments now have a single solution to manage their digital asset lifecycle – from custody to transactions to settlement – that helps them meet compliance obligations while being integration-ready.

IBM Corporation logo.
IBM Corporation logo.

Developed in collaboration with Dfns, a leading digital wallet infrastructure provider, IBM Digital Asset Haven integrates the full-stack infrastructure and security of IBM with Dfns digital asset custody and management capabilities. The Dfns platform has created 15 million wallets for over 250 clients, furthering its commitment to support complex compliance, performance, and security requirements.

With the adoption of tokenized assets and stablecoins increasing, institutions will need to evolve. The digital asset space presents a critical opportunity for financial institutions modernizing their product portfolios. IBM Digital Asset Haven empowers these institutions to participate in this new economy with the security and technical assurance for which IBM has become renowned in other mission-critical operations. Designed to be a holistic solution with industry-leading security, IBM Digital Asset Haven can provide clients with native support for key residency controls, programmable multi-party approvals, and policy-driven governance frameworks.

Its key features include:

  • Transaction Lifecycle Management supports the blockchain transaction process, from automation and routing to monitoring and settlement, across more than 40 connected public and private blockchains.
  • Governance and Entitlement Management via a unified framework for wallet access, policy enforcement, and transaction approvals. It’s supported by multi-party authorization workflows configurable for a broad range of operational scenarios.
  • Integrated Third-Party Solutions designed to accelerate deployment with pre-integrated services for identity verification (KYC), financial crime prevention (AML), yield generation, and more. Clients can implement additional integrations via developer-friendly REST APIs, SDKs, and tools. This strategy positions partners and developers to integrate their solutions with IBM Digital Asset Haven to accelerate innovation.
  • Holistic Security and Key Management is built on IBM’s infrastructure for secured digital asset operations, including support for Multi-Party Computation (MPC) and Hardware Security Module (HSM)-based signing using the IBM Crypto Express 8S HSMs embedded in IBM Z and LinuxONE. IBM Digital Asset Haven also integrates IBM Offline Signing Orchestrator (IBM OSO) for secured cold storage operations, which are required by regulatory bodies in an increasing number of jurisdictions globally. Combined with quantum-safe cryptography guidance, this approach is built to give regulated institutions the flexibility to generate, rotate, and store cryptographic keys to support their compliance requirements with jurisdictional mandates while also helping to prepare digital asset security against emerging, potential quantum threats.

“With IBM Digital Asset Haven, our clients have the opportunity to enter and expand into the digital asset space backed by IBM’s level of security and reliability,” said Tom McPherson, General Manager, IBM Z and LinuxONE. “This new, unified platform delivers the resilience and data governance they have been asking for, empowering governments and enterprises to build the next generation of financial services.”

“For digital assets to be integrated into core banking and capital markets systems, the underlying infrastructure must meet the same standards as traditional financial rails,” said Clarisse Hagège, CEO of Dfns. “Together with IBM, we’ve built a platform that goes beyond custody to orchestrate the full digital asset ecosystem, paving the way for digital assets to move from pilot programs to production at a global scale.”

Availability
IBM Digital Asset Haven is expected to be available via SaaS in Q4 2025 and Hybrid SaaS leveraging LinuxONE and/or IBM Z in Q4 2025, and is planned for on–premises in Q2 2026. For more information, visit www.ibm.com/products/digital-asset-haven.

Statements regarding IBM’s future direction and intent are subject to change or withdrawal without notice and represent goals and objectives only.

About IBM
IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM’s long-standing commitment to trust, transparency, responsibility, inclusivity, and service. 

Additional Sources 

Media Contact:
Chase Skinner
IBM Communications
chase.skinner@ibm.com

Maud Tezenas du Montcel
Dfns Marketing & Communications
press@dfns.co

KPMG Successfully Hosts the Inaugural Future Entrepreneur Award Ceremony to Support High-Quality Development of the Private Sector

By
Advertorial Desk
-

HONG KONG SAR – Media OutReach Newswire – 27 October 2025 – Currently, with continuous innovation momentum being released, emerging industries, the digital economy, and green development are bringing new growth drivers for the high-quality development of the Chinese economy. The private sector plays a fundamental role in this process, with private enterprises and entrepreneurs being indispensable forces. At the national level, a series of policies has been introduced to promote the growth of the private sector, further optimising the development environment for private enterprises, stabilising expectations, and stimulating vitality. A group of resilient and visionary private entrepreneurs actively practice new development concepts and promote the spirit of entrepreneurship, contributing to industrial upgrades, cultivating new productive forces, and advancing Chinese-style modernisation.

On 24 October, the inaugural KPMG Future Entrepreneur Award ceremony was held in Shenzhen. Since the award was officially launched in March this year, it has undergone several months of rigorous selection and professional evaluation, recognising a group of outstanding entrepreneurs for their exceptional contributions to long-term enterprise development, innovation, internationalisation, and social responsibility. While achieving good business results, they have demonstrated forward-looking planning and solid practices for sustainable enterprise development, showing significant advantages in technological innovation and international competition.

This selection focused on the inheritance and breakthroughs, innovation, and sustainable development of Chinese private enterprises. The award ceremony attracted representatives of entrepreneurs, experts, and scholars from across the country, who gathered to discuss how enterprises can achieve orderly inheritance, governance upgrades, and innovative breakthroughs in the context of the new economy. Jacky Zou, Chairman, KPMG China, states, “The spirit of Chinese entrepreneurship continues to evolve with national development. Today’s ‘Future Entrepreneurs’ are pioneers who break through to lead continuous innovation and plan for inheritance. They are bringing a qualitative leap to China’s economic development with ‘new productive forces’, becoming the core engine in the modernisation process. KPMG hopes to uncover truly ‘future-oriented’ successful entrepreneurs through the establishment of the Future Entrepreneur Award, focusing on five core areas: strategic foresight, innovation, governance optimisation, operational resilience, and social responsibility. KPMG will also continue to leverage its expertise to support and assist in enterprise growth.”

Four awards highlight the diverse ecosystem of future entrepreneurs

During the ceremony, the four awards were announced: ‘Future Entrepreneur of the Year’, ‘Extraordinary Female Future Entrepreneur’, ‘Excellent Family Business Future Entrepreneur’, and ‘Outstanding Emerging Future Entrepreneur’. The awardees included not only technology entrepreneurs who have made breakthroughs in high-end manufacturing, new energy, and digital transformation but also exemplary business operators who have achieved generational handover through institutional governance and cultural inheritance, reflecting the leadership and forward-looking vision of entrepreneurs in the new era.

Michael Jiang, Head of Clients and Markets at KPMG China, states, “The Future Entrepreneur Award gather entrepreneurs from different stages of development. We hope that through this platform, mature entrepreneurs can see new trends and new forces, while growing entrepreneurs can more quickly integrate into an excellent business ecosystem, establishing a long-lasting connection mechanism of ‘common progress and co-creating the future’. Entrepreneurs are not only drivers of economic growth but also bearers of social responsibility. The spirit of ‘Future Entrepreneurs’ should embody both innovation awareness and long-termism, daring to embrace change and promote breakthroughs in technology and business models while also being able to calmly build sustainable capabilities and organisations.”

Forward-looking planning: exploring the path of transformation and innovation for private enterprises

In the face of the current complex environment and intense competition, private enterprises are embarking on paths of transformation and upgrading. The future entrepreneurs awarded this time are representatives who have grown through innovation and iteration. They either lead their companies to become leaders in niche markets, achieve efficiency improvements through digital transformation, or expand their reach through globalisation, transitioning from ‘going out’ to ‘going in’. As these family-owned enterprises gradually enter a period of succession, both first-generation entrepreneurs and second-generation managers need not only traditional business operation skills but also mastery of digital tools, green transformation thinking, and cross-cultural communication skills. High-end manufacturing, green energy, digitalisation, and intelligent transformation are becoming new competitive focal points for family businesses.

In the face of these challenges, Karmen Yeung, National Head of Private Enterprise at KPMG China, states, “Family businesses can establish sound corporate governance systems to promote succession planning. Involving future successors in the design of these systems, organisational and management structure adjustments, as well as the establishment of important compliance and risk management systems, is more beneficial for a smooth inheritance transition. Additionally, considering the unique characteristics of family businesses, entrepreneurs can establish scientific and systematic family risk management systems and family governance frameworks to enhance overall risk control and response capabilities. Regarding human resources, family businesses can introduce a professional managerial succession mechanism to bring in professional management teams through market-oriented methods. This allows family members to participate in a wider variety of investment management, while also contributing more to society and achieving effective risk diversification.”

The KPMG Future Entrepreneur Award is not only a recognition of outstanding entrepreneurs but also a profound interpretation of the spirit of entrepreneurship by KPMG, as well as a deep reflection and practical support for the future development of the private sector. Gary Zhou, Chief Marketing Officer at KPMG China, states, “Under the dual opportunities of policy and market, the awarded entrepreneurs demonstrate the characteristics of the entrepreneurial spirit in the new era. They navigate with innovation as their vessel and expand their territories with globalisation as their sail, all while shouldering the generational inheritance of enterprise spirit. Their practices are continuously injecting resilience and vitality into the high-quality development of the Chinese economy.”
Hashtag: #KPMG

The issuer is solely responsible for the content of this announcement.

About KPMG

KPMG in China has offices located in 31 cities with over 14, 000 partners and staff, in Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Dongguan, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Nanjing, Nantong, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Tianjin, Wuhan, Wuxi, Xiamen, Xi’an, Zhengzhou, Hong Kong SAR and Macau SAR. It started operations in Hong Kong in 1945. In 1992, KPMG became the first international accounting network to be granted a joint venture licence in the Chinese Mainland. In 2012, KPMG became the first among the “Big Four” in the Chinese Mainland to convert from a joint venture to a special general partnership.

KPMG is a global organisation of independent professional services firms providing Audit, Tax and Advisory services. KPMG is the brand under which the member firms of KPMG International Limited (“KPMG International”) operate and provide professional services. “KPMG” is used to refer to individual member firms within the KPMG organisation or to one or more member firms collectively.

KPMG firms operate in 142 countries and territories with more than 275,000 partners and employees working in member firms around the world. Each KPMG firm is a legally distinct and separate entity and describes itself as such. Each KPMG member firm is responsible for its own obligations and liabilities.

Celebrating 80 years in Hong Kong

In 2025, KPMG marks “80 Years of Trust” in Hong Kong. Established in 1945, we were the first international accounting firm to set up operations in the city. Over the past eight decades, we have woven ourselves into the fabric of Hong Kong, working closely with the government, regulators, and the business community to help establish Hong Kong as one of the world’s leading business and financial centres. This close collaboration has enabled us to build lasting trust with our clients and the local community – a core value celebrated in our anniversary theme: “80 Years of Trust”.

National Center of Technology Innovation for Dairy Debuts at the IDF World Dairy Summit, Showcasing Innovation to Drive Sustainability

By
Advertorial Desk
-

SANTIAGO, Chile, Oct. 27, 2025 /PRNewswire/ — The highly anticipated 2025 IDF World Dairy Summit took place from October 20 to 23 in Santiago, Chile. Drawing global attention, the event served as an important barometer for the future of the dairy industry.

Liu Chunxi, Chairman of the National Center of Technology Innovation for Dairy (NCTID) and Senior Executive President of Yili Group, was invited to the meeting of the IDF Task Force on the Paris Dairy Declaration on Sustainability, where he joined global dairy leaders, experts, and scholars in discussions on the industry’s sustainable development.

NCTID’s achievements in sustainable innovation were recognized with multiple honors at this year’s IDF Dairy Innovation Awards—often dubbed the “Oscars” of the dairy sector for their global scope, professional rigor, and industry impact.

National Center of Technology Innovation for Dairy Debuts at the IDF World Dairy Summit, Showcasing Innovation to Drive Sustainability
National Center of Technology Innovation for Dairy Debuts at the IDF World Dairy Summit, Showcasing Innovation to Drive Sustainability

AMBPOMIAL’s “For a Bluer Ocean” Limited-Edition Eco-Packaging received the Innovation in Packaging and Transparency for Dairy Products award. The product features an eco-friendly bottle label that utilizes the alkali-washable ink technology pioneered by NCTID, allowing labels to rapidly detach from the bottles during recycling. This significantly improves the purity of recycled materials and boosts recovery rates, contributing to a greener future.

Yili’s Xinhuo Bone Energy Formula Milk Powder received the Innovation in Dairy Products for Human Nutrition award. Built on an integrated bone–joint–muscle nutrition approach informed by traditional Oriental dietary principles, the formula combines protein, colostrum basic protein (CBP), calcium, vitamins, sodium hyaluronate, Eucommia leaf powder, and Polygonatum powder to effectively support bone, joint, and muscle health.

Dr. Ignatius Szeto, Executive Director of Nutrition and Health Research Center at NCTID and Assistant President of Yili Group, was invited to deliver a keynote presentation titled “The Role of Dairy Consumption in Healthy Aging.” He elaborated on five core health dimensions, underscoring the multiple benefits of dairy products in promoting healthy aging. He also shared NCTID’s cutting-edge research findings that provide vital evidence and practical strategies to help address global aging challenges. Dr. Szeto noted that dairy products, as nutrient-rich sources of high-quality protein and key vitamins and minerals, play an indispensable role in improving nutritional adequacy in adults and contributing to reducing the prevalence of non-communicable diseases and other age-related health conditions.

NCTID was established under the leadership of Yili Group. As a key partner in the center’s establishment and operations, Yili has been instrumental in driving the development and implementation of its cutting-edge technologies, thereby promoting collective progress across the industry. During the summit, NCTID showcased a range of innovations, including a digital traceability system for microbial risk management in dairy products and a research project highlighting the protective role of fermented dairy in mitigating alcohol-related liver stress. These demonstrations fully reflected the center’s strong capabilities in dairy technology innovation.

Moving forward, NCTID will remain committed to technological innovation. By deepening industry-academia-research collaboration, promoting the commercialization of research outcomes, and driving industrial upgrading and sustainability, it will offer Chinese wisdom and strength for a healthier world.

Jiuzi Holdings, Inc. Partners with SOLV Foundation on $2.8B TVL Bitcoin Initiative to Advance Crypto Treasury Strategy

By
Advertorial Desk
-

HANGZHOU, China, Oct. 27, 2025 /PRNewswire/ — Jiuzi Holdings, Inc. (NASDAQ: JZXN; “the Company”) today announced it has entered into a Strategic Cooperation Agreement with the SOLV Foundation, a cross-chain Bitcoin staking and structured finance platform boasting a total value locked (TVL) of US$2.8 billion. This collaboration underscores the Company’s ambition as a Nasdaq-listed leader focused on building its treasury around Bitcoin as its primary digital asset holding.

JZXN will leverage SOLV’s platform to maximize the efficiency of its Bitcoin holdings. Bitcoin assets held by the Company or its subsidiaries will be deposited into the SOLV platform under custody by approved, regulated third parties designated by the Company, ensuring transparency, security, and institutional-grade auditability.

Furthermore, senior representatives from both JZXN and SOLV will form a Steering Committee tasked with spearheading transformative initiatives to redefine Bitcoin-centric decentralized finance (DeFi). This committee will drive adoption of SolvBTC across networks including Solana, Base; facilitate market expansion; and pioneer innovative financial models such as tokenized real-world assets and structured yield products.

This agreement reflects the shared vision of positioning the Company as a Bitcoin-focused crypto financial firm, integrating its reserves with cutting-edge digital asset strategies. By tapping into SOLV’s expertise in Bitcoin liquidity aggregation and staking, JZXN aims to provide shareholders with institutional exposure to Bitcoin while enhancing capital efficiency within a regulated framework. Both parties affirm that this partnership will operate under principles of transparency, sound governance, and compliance with U.S. Securities and Exchange Commission (SEC) regulations and Nasdaq listing requirements.

Mr. Li Tao, Chief Executive Officer of Jiuzi Holdings, Inc., stated: “This partnership marks a transformative step forward, strengthening our Bitcoin vault strategy and aligning us with one of the most advanced platforms in the Bitcoin liquidity and staking ecosystem.”

Ryan Chow, Co-Founder of Solv Protocol, said, “Our expertise in managing large-scale Bitcoin assets, combined with Jiuzi’s NASDAQ-listed status, builds a bridge of trust for traditional finance. Together, we’re enabling secure institutional capital flow into crypto.”

About Jiuzi Holdings, Inc.

Jiuzi Holdings, Inc. is a leading provider of NEV intelligent charging infrastructure in China’s lower-tier cities. The Company specializes in high-power DC fast charging stations integrated with energy storage systems and plans continued expansion through 2026 to support China’s carbon neutrality goals and sustainable transportation. For more information, visit jzxn.com.

 

Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner

By
Advertorial Desk
-

SYDNEY, Oct. 27, 2025 /PRNewswire/ — Kazia Therapeutics Limited (“Kazia” or the “Company”) today announced its intention to request and hold a follow-up Type C meeting with the U.S. Food & Drug Administration (FDA) to discuss overall survival (OS) findings in newly diagnosed glioblastoma (GBM) patients treated with paxalisib and to seek agency feedback on a potential regulatory pathway aligned with the FDA Oncology Center of Excellence’s Project FrontRunner initiative.

“GBM remains one of the most lethal cancers with limited therapeutic options. In line with the FDA Oncology Center of Excellence’s Project FrontRunner initiative, we intend to engage the Agency to discuss whether the overall survival data generated in newly diagnosed GBM patients treated with paxalisib may be adequate to support a conditional approval pathway,” said Dr. John Friend, M.D., Chief Executive Officer of Kazia Therapeutics. “Consistent with this framework, Kazia will propose initiation of the post-approval, randomized Phase 3 confirmatory study prior to submission of the NDA, ensuring that our regulatory strategy fully reflects the FDA’s renewed emphasis on overall survival as the most meaningful endpoint for patients and clinicians.”

In its recently issued draft guidance, the FDA stated that overall survival is the “gold standard” endpoint in oncology and “should be prioritized as the primary endpoint when feasible,” particularly in diseases with a short natural history where survival can be reliably assessed. Kazia believes GBM is precisely such a setting and intends to present survival analyses, supporting clinical safety, and planned confirmatory trial design for FDA discussion.

Project FrontRunner is an FDA Oncology Center of Excellence initiative encouraging sponsors to consider when it may be appropriate to seek approval of cancer drugs for advanced or metastatic disease in an earlier clinical setting, rather than the traditional approach of developing therapies only for patients who have exhausted available treatment options.

As announced in July 2024, in the prespecified secondary analysis in newly diagnosed (up-front) unmethylated GBM patients, median OS was 15.54 months in the paxalisib arm (n = 54) versus 11.89 months for concurrent standard of care (SOC) (n = 46). Kazia intends to reference Project FrontRunner principles in its Type C briefing package, including an OS-driven confirmatory study plan in newly diagnosed GBM.

“We are moving decisively to bring paxalisib forward in GBM using the endpoints that matter most to patients and physicians,” added Dr. Friend. “Our objective is to work collaboratively with the FDA under the guiding principles of Project FrontRunner to pursue a conditional approval in the front-line treatment setting of glioblastoma. In parallel, Kazia will initiate the post-approval, randomized Phase 3 study prior to filing the NDA, ensuring that our development plan fully aligns with the Agency’s modernized, patient-focused framework.”

Kazia also notes that leading oncology companies have begun publicly referencing Project FrontRunner in successful FDA actions, underscoring the initiative’s growing relevance for sponsors developing first-line or earlier-setting therapies.

For investor and media, please contact Alex Star, Managing Director LifeSci Advisors LLC, Astarr@lifesciadvisors.com, +1-201-786-8795.

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, an investigational brain penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase 2/3 study in glioblastoma (GBM-Agile) was reported in 2024 and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma by the FDA in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumor types and has provided evidence of synergy with immuno-oncology agents. A Phase I study has been completed and preliminary data was presented at 15th Biennial Ovarian Cancer Research Symposium in September 2024. For more information, please visit www.kaziatherapeutics.com or follow us on X @KaziaTx.

Forward-Looking Statements

This announcement contains forward-looking statements, which can generally be identified as such by the use of words such as “may,” “will,” “plan,” “intend,” “estimate,” “future,” “forward,” “potential,” “anticipate,” or other similar words. Any statement describing Kazia’s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward looking statements, including, but not limited to, statements regarding: Kazia’s intention to request and hold a Type C meeting with the FDA to discuss OS findings in GBM patients treated with paxalisib and to seek agency feedback on a potential regulatory pathway, the plan to propose initiation of the post-approval, randomized Phase 3 confirmatory study prior to submission of the NDA, the intention to present survival analyses, supporting clinical safety and planned confirmatory trial design for FDA discussion, Kazia’s intention to reference Project FrontRunner principles in its Type C briefing package, the objective to work collaboratively with the FDA under the guiding principles of Project FrontRunner, the plan to pursue a conditional approval in the front-line treatment setting of GBM, the plan to initiate the post-approval, randomized Phase 3 study prior to filing the NDA, the goal of ensuring that Kazia’s development plan and regulatory strategy fully reflects and aligns with the FDA’s framework and emphasis, the timing for results and data related to Kazia’s clinical and preclinical trials, Kazia’s strategy and plans with respect to its paxalisib program, the potential benefits of paxalisib, timing for any regulatory submissions or discussions with regulatory agencies and the potential market opportunity for paxalisib. Such statements are based on Kazia’s current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties associated with clinical and preclinical trials and product development, including the risk that interim or early data may not be consistent with final data, risks related to regulatory approvals, risks related to the impact of global economic conditions and U.S. government shutdown, and risks related to Kazia’s ability to regain and/or maintain compliance with the applicable Nasdaq continued listing requirements and standards. These and other risks and uncertainties are described more fully in Kazia’s Annual Report, filed on form 20-F with the SEC, and in subsequent filings with the United States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement.

ISX Financial EU PLC Appoints Group CFO Ajay Treon to the Board of Directors as Executive Director

By
Advertorial Desk
-

NICOSIA, Cyprus, Oct. 27, 2025 /PRNewswire/ — ISX Financial EU Plc (“ISXX”), an EEA-authorised Electronic Money Institution and banktech provider of transactional banking and real-time payments across Europe and the UK, is pleased to announce the appointment of Mr. Ajay Treon, Group Chief Financial Officer, as an Executive Director on the Company’s Board of Directors. The appointment follows a non-objection by the Eurosystem Central Bank of Cyprus, home regulator of ISXX.

With an impressive 25-year career in the banking industry, including extensive experience in renowned institutions such as Lloyds Banking Group, Lehman Brothers, Dresdner Kleinwort Investment Bank, and Credit Suisse, Mr. Treon brings a wealth of expertise in financial management, strategic planning, and risk mitigation. He also possesses valuable experience in the fintech sector, further enhancing his understanding of the evolving financial landscape. Mr. Treon is a qualified accountant, holds an Executive MBA, and possesses the esteemed Certificate in Quantitative Finance.

Since Mr. Treon assumed the role of Group Chief Financial Officer in July 2023, ISXX has delivered sustained profitability and rigorous cost discipline, including record performance in 2024 and continued resilience throughout 2025. The Group has strengthened Own Funds and Net Assets, maintained robust EBITDA margins, and continued to invest in innovation, core technology, and talent to support scale. Treasury, safeguarding, and reporting frameworks have been enhanced, aligning capital deployment with growth in open banking (A2A), e-money, and acquiring operations.

Mr. Takis Taoushanis, ISXX Chairman of the Board of Directors, said: “Mr. Treon’s appointment strengthens the Board’s financial and risk oversight at a time when settlement infrastructure, safeguarding, and capital discipline are central to execution. His vast experience across tier-one institutions and his contribution to ISXX’s recent performance make him a valuable addition to the Board of Directors.”

Mr. Ajay Treon, Group CFO and Executive Director of ISXX, said: “I am honoured to join the Board of Directors and remain fully committed to advancing the Company’s strategic priorities, strengthening capital resilience, scaling our transactional banking capabilities, and maintaining rigorous financial governance. Our focus continues to be on delivering consistent, profitable growth through operational discipline and transparent reporting, as we execute on our expanding product portfolio and market strategy.”

Mr. Nikogiannis Karantzis, ISXX Managing Director & CEO, commented: “Mr. Treon’s appointment to the Board formalises the financial and risk discipline he has helped embed across the ISXX Group, and supports our execution as we scale transactional banking and Open Banking services across the EU and UK.”

About ISX Financial EU PLC
Headquartered in Nicosia, ISX Financial EU Plc (ISXX, LEI: 213800NGHVYL5PFZI692) is a leading banktech company EEA authorised as an Electronic Money Institution by the Central Bank of Cyprus and regulated in the UK by the Financial Conduct Authority.

Website: www.isx.financial

Logo: https://laotiantimes.com/wp-content/uploads/2025/10/isx_logo-1.jpg

Iridium Unveils Revolutionary Global GPS Device Protection on a Chip

By
Advertorial Desk
-

Devices reliant on GPS and other Global Navigation Satellite Systems (GNSS) can integrate comprehensive protection against jamming, spoofing and time interruptions with the Iridium PNT ASIC

MCLEAN, Va., Oct. 27, 2025 /PRNewswire/ — Iridium Communications Inc. (NASDAQ: IRDM), a leading provider of global voice, data, and PNT satellite communications, today announced a leap forward in the security of GPS and other GNSS-reliant devices against jamming, spoofing and timing interruptions with the unveiling of a dedicated, miniature application-specific integrated circuit (ASIC), the Iridium® PNT ASIC. Engineered for seamless integration into a wide range of electronic devices, the Iridium PNT ASIC will deliver authenticated, pole-to-pole positioning, navigation, and timing (PNT) data. It will provide a resilient alternative to traditional GNSS, offering protection against spoofing and jamming for consumer, industrial, and government applications.

Iridium PNT ASIC
Iridium PNT ASIC

“This is a first. To provide this type of capability on a global basis has never been done before,” said Iridium CEO Matt Desch. “The size, low cost, and scalability of this solution to protect GPS is a major breakthrough.”

The jamming and spoofing of GNSS systems have gone from being an occasional threat to a near constant occurrence over the past few years. Several high profile events, like the September 2025 jamming of European Commission President Ursula von der Leyen’s aircraft navigation system and a malfunction of GNSS systems in the waters outside of Qatar, causing a pause in maritime operations in October 2025, are two recent examples. A September 2024 report from OPSGROUP cited a 500% increase in the spoofing of commercial airliners, specifically stating that on average 1,500 flights a day are encountering GPS spoofing.

Couple this dramatic rise in threats with the economic risks, estimated at billions of dollars per day globally, and the need for a simple, easily integrated solution is undeniable. For example, in 2019, a single day GPS outage in the United States was estimated by the U.S. National Institute of Standards and Technology (NIST) to cost the economy approximately $1 billion. When adjusted for inflation in 2025, this could be well over $1.3 billion per day.

Tiny Form Factor – Embedded Resilience

Measuring just 8mm by 8mm and capable of fitting into devices ranging from consumer products up through major infrastructure systems like power grids, transportation systems and telecom networks, the Iridium PNT ASIC democratizes GNSS resilience. When embedded in a device, the Iridium PNT ASIC receives a cryptographically secure time and location data signal from the Iridium satellite network that is 1,000 times more powerful than GPS and capable of working inside buildings. This can help GNSS-dependent applications to not only detect a problem but also maintain operations until it is resolved. The Iridium PNT ASIC will also continuously verify signal integrity, making it the ideal alternative or primary source of PNT data.

“The market for alternative PNT solutions is shifting rapidly toward compact, integrated technologies,” said Mike O’Connor, executive vice president, PNT, Iridium. “While Iridium PNT is already available in some systems, the Iridium PNT ASIC will take it to the next level to deliver the only truly global alternative to GPS in the smallest form factor available.”

The alternative PNT market is expected to reach $3.5 billion by 2032, driven by demand for secure, reliable timing and location data across all sectors of critical infrastructure. Available today, Iridium PNT protects digital infrastructure for financial markets, governments, and major corporations. Its applications span data centers, 5G wireless networks, aviation, maritime, land mobile, and IoT, making it a foundational service for the future of secure, connected systems.

“Whether in government, enterprise, or consumer applications, every device that relies on GNSS needs a dependable backup or reliable primary service in the event of disruption,” O’Connor said. “The Iridium PNT ASIC delivers that dependability in a compact, all-in-one chip.”

Iridium showcased the ASIC’s capabilities during last month’s Jammertest, an annual event that evaluates the resilience of GNSS and alternative PNT technologies under jamming and spoofing attacks. The Iridium PNT ASIC maintained both timing accuracy and reliable navigation during controlled exercises.

Iridium is inviting organizations to apply to participate in beta trials, and, if selected, they will receive Iridium PNT ASIC evaluation kits, enabling early integration and testing. The Iridium PNT ASIC is planned for commercial availability in mid-2026.

Organizations with devices that rely on GNSS and are seeking to enhance resilience against jamming, spoofing or time and frequency interruptions, or those developing innovative technologies in the PNT domain, are encouraged to learn more and express interest at www.iridium.com/pnt/asic.

Iridium is highlighting the Iridium PNT ASIC at the International Timing and Sync Forum (ITSF), held October 27th to 30th in Prague.

About Iridium Communications Inc.

Iridium® is the only mobile voice and data satellite communications network that spans the entire globe. Iridium enables connections between people, organizations, and assets to and from anywhere, in real time. Together with its ecosystem of partner companies, Iridium delivers an innovative and rich portfolio of reliable solutions for markets that require truly global communications. In 2024, Iridium acquired Satelles and its positioning, navigation, and timing (PNT) service. Iridium Communications Inc. is headquartered in McLean, Va., U.S.A., and its common stock trades on the Nasdaq Global Select Market under the ticker symbol IRDM. For more information about Iridium products, services, and partner solutions, visit www.iridium.com.

Forward-Looking Statements Disclosure

Statements in this press release that are not purely historical facts may constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. The Company has based these statements on its current expectations and the information currently available to us. Forward-looking statements in this press release include statements regarding the capabilities, benefits and availability of the Iridium PNT ASIC and related services. Forward-looking statements can be identified by the words “anticipates,” “may,” “can,” “believes,” “expects,” “projects,” “intends,” “likely,” “will,” “to be” and other expressions that are predictions or indicate future events, trends or prospects. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Iridium to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties regarding the development, marketing and availability of the Iridium PNT ASIC and related services, and the company’s ability to maintain the health, capacity and content of its satellite constellation, as well as general industry and economic conditions, and competitive, legal, governmental and technological factors. Other factors that could cause actual results to differ materially from those indicated by the forward-looking statements include those factors listed under the caption “Risk Factors” in the Company’s Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (the “SEC”) on February 13, 2025, as well as other filings Iridium makes with the SEC from time to time. There is no assurance that Iridium’s expectations will be realized. If one or more of these risks or uncertainties materialize, or if Iridium’s underlying assumptions prove incorrect, actual results may vary materially from those expected, estimated or projected. Iridium’s forward-looking statements speak only as of the date of this press release, and Iridium undertakes no obligation to update forward-looking statements.

Press Contact:  

Investor Contact:

Jordan Hassin    

Kenneth Levy

Iridium Communications Inc.   

Iridium Communications Inc.

Jordan.Hassin@Iridium.com    

Ken.Levy@Iridium.com

+1 (703) 287-7421  

+1 (703) 287-7570

 

 

CTF Life Harnesses the CTF Group Ecosystem to Forge Strategic Alliances with Three Major Hospitals Enhances Hospital and PrimeChamp Doctor Network to Empower Customers with Greater Autonomy, Convenience and Comprehensive Medical Services

By
Advertorial Desk
-

HONG KONG SAR – Media OutReach Newswire – 27 October 2025 – CTF Life today announced the signing of a Memorandum of Understanding with Gleneagles Hospital Hong Kong (“Gleneagles”), CUHK Medical Centre (“CUHKMC”), and Hong Kong Baptist Hospital (“HKBH”) to establish strategic partnerships. In a pioneering move, CTF Life has also become the first insurance company to collaborate with Gleneagles MediCentre in Admiralty to launch an exclusive programme to provide customers with health management solutions. At the same time, the PrimeChamp Doctor Network has been enhanced with the official inclusion of the three hospitals and their affiliated medical centres. This expanded medical network now spans across Hong Kong, offering customers priority referrals, appointment scheduling and direct billing services.

Man Kit Ip, Executive Director and Chief Executive Officer of CTF Life (middle); Ellick Tsui, Executive Director, Deputy Chief Executive Officer and Chief Financial Officer of CTF Life (second from right); Dr Kenneth Tsang, Regional Chief Executive Officer of IHH Healthcare North Asia and Chief Executive Officer of Gleneagles Hospital Hong Kong (second from left); Dr Chung Kin Lai, Chief Executive Officer of CUHK Medical Centre (first from right); and Dr Leung Chi Bon, Chief Executive Officer of Hong Kong Baptist Hospital (first from left), announce the establishment of strategic partnerships at the kick-off ceremony.
Man Kit Ip, Executive Director and Chief Executive Officer of CTF Life (middle); Ellick Tsui, Executive Director, Deputy Chief Executive Officer and Chief Financial Officer of CTF Life (second from right); Dr Kenneth Tsang, Regional Chief Executive Officer of IHH Healthcare North Asia and Chief Executive Officer of Gleneagles Hospital Hong Kong (second from left); Dr Chung Kin Lai, Chief Executive Officer of CUHK Medical Centre (first from right); and Dr Leung Chi Bon, Chief Executive Officer of Hong Kong Baptist Hospital (first from left), announce the establishment of strategic partnerships at the kick-off ceremony.

Man Kit Ip, Executive Director and Chief Executive Officer of CTF Life, said, “We are pleased to forge long-term business partnerships with three leading and distinguished hospitals. Harnessing the strengths of the Chow Tai Fook Group ecosystem, we are committed to providing our customers with more flexible and superior medical service solutions, serving as their Life Planner. This collaboration not only further solidifies our medical network across Hong Kong, but also elevates the overall service experience at CTF Life, empowering customers with greater autonomy, convenience and comprehensive medical service experiences at every stage of their life journey. We firmly believe that medical protection should go beyond claims, it should accompany our customers across every stage from prevention and diagnosis to treatment and recovery, truly bringing to life our vision of creating value beyond healthcare.”

Territory-wide Medical Network Coverage Across Hong Kong

The three hospitals will respectively serve as CTF Life’s designated medical network partners on Hong Kong Island, Kowloon, and the New Territories. Their doctors and mental health therapists will also join the PrimeChamp Doctor Network, providing customers with convenient, high-quality, and comprehensive medical services.

Hong Kong Island: Gleneagles Hospital Hong Kong

Gleneagles serves as the appointed medical network partner for Hong Kong Island. CTF Life has also become the first insurance company to collaborate with the newly opened Gleneagles MediCentre in Admiralty, further expanding its service scope through exclusive programmes. These programmes include gastroscopy, colonoscopy and wart removal services, providing customers with prevention-oriented health management solutions.

New Territories: CUHK Medical Centre

CUHKMC will serve as the selected medical network partner for the New Territories. Backed by a top-tier medical team comprising professors from the CUHK Faculty of Medicine and specialists, coupled with advanced medical facilities and strong research capabilities, CUHKMC provides customers with premium, multi-specialty medical services. Dedicated to translating cutting-edge international medical research into clinical practice, CUHKMC delivers a world-class diagnostic and treatment experience that benefits both customers and the wider community.

Kowloon: Hong Kong Baptist Hospital

HKBH will serve as the designated medical network partner for Kowloon. Operating under a “One Hospital, Multiple Service Sites” synergy model, the hospital enables patients to conveniently access medical services close to their preferred location. Among these sites, the HKBH East Kowloon Medical Centre (EKMC), located in the Kwun Tong Business District (Ngau Tau Kok), provides pre-approved direct billing services for cataract surgery and oncology treatments. Additionally, mental health team offers professional guidance to help individuals better understand and manage their psychological well-being. Together, these services embrace the Hospital mission: “In the Service of Man, for the Glory of God.”

Customer-Exclusive Medical Services Reflects a People-Centric Approach

Through this collaboration, the three hospitals will offer the following services for CTF Life customers:

  • Priority referral and appointment scheduling, significantly reducing waiting time.
  • Direct billing services, allowing customers to receive treatment without upfront payment, easing financial pressure.
  • One-stop cancer treatment services, covering diagnosis, treatment, and post-surgery rehabilitation, providing comprehensive support throughout the care journey.
  • Access to premium medical services and coordination, arranging professor-level doctors and advanced medical facilities to ensure customers receive the highest quality of medical care.

Hashtag: #CTFLife #周大福人壽

The issuer is solely responsible for the content of this announcement.

About CTF Life

Chow Tai Fook Life Insurance Company Limited (“CTF Life”) is proud of its rich, 40-year legacy in Hong Kong. CTF Life is a wholly-owned subsidiary of CTF Services Limited (“CTFS”) (Hong Kong Stock Code: 659) and one of the most well-established life insurance companies in Hong Kong. As a member of Chow Tai Fook Enterprises Limited, CTF Life consistently strengthens its collaboration with the Chow Tai Fook Group ecosystem to support customers and their loved ones in navigating life’s journey with personalised planning solutions, lifelong protection and diverse lifestyle experiences. By leveraging the Group’s robust financial strength and strategic investments across the globe, CTF Life aspires to become a leading insurance company in Asia while continuously creating value beyond insurance.

1...1,9251,9261,927...6,382Page 1,926 of 6,382